Physician profile
Daisy Merey
NPI 1073626859
$2,106.10
in general payments reported to CMS, 2019-2025
12 companies · $43.14 in 2025
The $43.14 reported for 2025 was less than what a typical Adult Medicine provider received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.81 · 2020: $251 · 2021: $217 · 2022: $958 · 2023: $186 · 2024: $384 · 2025: $43.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $612.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Musculoskeletal Transplant Foundation INC. | $839.86 | 2022 | |
| Pfizer INC. | $283.72 | 2022-2023 | |
| Galderma Laboratories, L.P. | $244.36 | 2020-2021 | |
| Allergan, INC. | $146.27 | 2019-2020 | |
| Abbvie INC. | $136.76 | 2024 | |
| Esperion Therapeutics, INC. | $125.00 | 2024 | Nexletol, Nexlizet |
| Lilly USA, LLC | $121.84 | 2024 | Mounjaro |
| Novo Nordisk INC | $105.72 | 2021-2022 | |
| Exact Sciences Corporation | $43.14 | 2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $26.24 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $20.90 | 2019 | |
| Currax Pharmaceuticals LLC | $12.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daisy Merey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.